KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Receivables - Other (2020 - 2023)

Pfizer (PFE) has disclosed Receivables - Other for 8 consecutive years, with $57.0 million as the latest value for Q2 2023.

  • On a quarterly basis, Receivables - Other fell 57.14% to $57.0 million in Q2 2023 year-over-year; TTM through Apr 2023 was $57.0 million, a 57.14% decrease, with the full-year FY2022 number at $167.0 million, down 15.23% from a year prior.
  • Receivables - Other was $57.0 million for Q2 2023 at Pfizer, down from $167.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $871.0 million in Q2 2021 to a low of $53.0 million in Q4 2021.
  • A 4-year average of $287.2 million and a median of $197.0 million in 2021 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: plummeted 86.78% in 2021, then fell 15.23% in 2022.
  • Pfizer's Receivables - Other stood at $401.0 million in 2020, then tumbled by 86.78% to $53.0 million in 2021, then skyrocketed by 215.09% to $167.0 million in 2022, then plummeted by 65.87% to $57.0 million in 2023.
  • Per Business Quant, the three most recent readings for PFE's Receivables - Other are $57.0 million (Q2 2023), $167.0 million (Q4 2022), and $272.0 million (Q3 2022).